Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug ahead of push to FDA

Japan-based Kyowa Kirin is fronting $330 million and pledging up to $1.1 billion in milestones to split the U.S. profits of Kura Oncology’s phase 2-stage oral leukemia treatment as well as to secure the commercialization rights for the rest of the world.